

# ワクチン・アジュバント研究センター

Center for Vaccine and Adjuvant Research(CVAR) Kick-Off Meeting

## キックオフ ミーティング

同時開催：2nd Asia Vaccine and Immunotherapeutic Workshop

2017年10月20日（金） / October 20, 2017

千里ライフサイエンスセンター / Senri Life Science Center, Osaka, Japan

< 主催 / Organizer >

国立研究開発法人医薬基盤・健康・栄養研究所 ワクチン・アジュバント研究センター  
Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)



国立研究開発法人  
医薬基盤・健康・栄養研究所  
National Institutes of  
Biomedical Innovation, Health and Nutrition

< 協賛 / Supporting organization >

国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development (AMED)



国立研究開発法人 日本医療研究開発機構  
Japan Agency for Medical Research and Development

## Contents / 目次

Introducing CVAR / CVARのご紹介 ..... P  
~ P


Program / プログラム

ム ..... P ~ P

Abstracts for oral presentation / 講演要旨 ..... O  
~ O

Abstracts for poster presentation / ポスター発表要旨 ..... P ~  
P

## Venue / 会場



### Venue

#### ◆ Oral presentation

13:00-14:40

15:20-17:00

#### ◆ Poster presentation

14:40-15:20

**Notice / 注意**

(1) Smoking is allowed only in the designated room on the 6th floor.

喫煙される方は、6階の喫煙場所をお願いします。館内のそれ以外の場所での喫煙は禁じられています。

(2) Please turned off your cell phone or put them on vibrate during the presentations.

講演中は、携帯電話は電源を切るかマナーモードにしてください。

# Program for oral presentation / 講演プログラム

## ■ Registration (12:30)

### 1. Opening remarks (13:00)

Yoshihiro Yoneda, MD, Ph.D.

/ Director General of National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)

### 2. 2<sup>nd</sup> Asia Vaccine and Immunotherapeutic Workshop ~ Special lectures for Asian Vaccine R&D (13 : 05~14:40)

< session chair > Ken J. Ishii / NIBIOHN

#### 【O-01】 13:05~13:10

「Introduction and future perspective of ISV」

Margaret Ann Liu, MD / President, International Society for Vaccines

(ProTherImmune / Karolinska Institutet / University of California, San Francisco)

#### 【O-02】 13:10~13:40

「Clinical development of SE36 malaria vaccine」

Toshihiro Horii, Ph.D. / Department of Molecular Protozoology, Research Institute for Microbial Diseases (RIMD), Osaka University

#### 【O-03】 13:40~14:10

「Manipulating Adjuvants to achieve augmented or suppressive immune responses」

Bin Wang, Ph.D. / Key Lab for Medical Molecular Virology of MOE & MOH, Shanghai Medical College, Fudan University and National Engineering Lab for Therapeutic Vaccines, China

#### 【O-04】 14:10~14:40

「Flagellin as a versatile adjuvant for vaccines against intractable diseases」

Joon Haeng Rhee, MD, Ph.D. / Clinical Vaccine R&D Center and Department of Microbiology, Chonnam National University Medical School, Gwangju, Republic of Korea

### 3. Poster session & Coffee break (14:40~15:20)

◆Please feel free to come to Science Hall. Poster presenters will stand by their poster and be prepared to answer questions from attendees.

◆Please help yourself to some coffee at the lobby.

#### **4. Center for Vaccine and Adjuvant Research (CVAR) Kick-Off meeting (15:20~17:00)**

< session chair > Ken J. Ishii / NIBIOHN

##### **◆Opening remarks (15:20~15:30)**

Kazunari Asanuma, MD / Director of Health Sciences Division, Ministry of Health, Labour and Welfare

##### **【O-05】 15:30~15:50**

「Nucleic acids as an vaccine adjuvant and potential immunotherapeutics」

Ken J. Ishii, MD, Ph.D. / Center for Vaccine and Adjuvant Research (CVAR), NIBIOHN

##### **【O-06】 15:50~16:10**

「Diets and commensal bacteria act as natural adjuvants for the control of intestinal immune responses against oral vaccines」

Jun Kunisawa, Ph.D. / Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN

##### **【O-07】16:10~16:30**

「Recombinant BCG expressing SOCS1 antagonist as a novel BCG vaccine」

Yasuhiro Yasutomi, DVM, Ph.D. / Laboratory of Translational Immunology and Tsukuba Primate Research Center, NIBIOHN

##### **【O-08】16:30~16:50**

「Dynamic changes in host histone modifications and chromatin architectures to influenza virus infection」

Yumiko Imai, MD, Ph.D. / Laboratory of Regulation of Intractable Infectious Diseases, NIBIOHN

#### **6. Closing remarks (16:50)**

Koichi Yamanishi, MD, Ph.D. / Director General of the research foundation for microbial disease of Osaka University

# Program for poster presentation / ポスター発表プログラム

【 October 20, 2017 (14:40 ~ 15:20)】

■ **Poster session : Poster presenters will stand by their poster and be prepared to answer questions from attendees from 14:40 to 15:20.**

【P-01】

Title: Immunological mechanism of Ag85B-hPIV2-based anti-tuberculosis vaccine

(Ag85B-hPIV2 結核ワクチンの免疫誘導のメカニズム)

First author : 長竹 貴広 / Takahiro Nagatake

Affiliation : Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN)

【P-02】

Title: Development of a divalent food poisoning vaccine using C-terminal fragment of *Clostridium perfringens* enterotoxin and cholera toxin B subunit

(ウエルシュ菌エンテロトキシンC末断片とコレラトキシンBサブユニットを用いた食中毒多価ワクチンの開発)

First author : 鈴木 英彦 / SUZUKI Hidehiko

Affiliation : Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN

【P-03】

Title: Prime-boost Vaccination with CpG ODN and curdlan strongly induces both systemic and mucosal immunity

(CpG ODN とカードランを用いたプライム - ブーストワクチン法は全身免疫と粘膜免疫の両方を強く誘導する)

First author : 武村 直紀 / Naoki Takemura

Affiliation :<sup>1</sup> Department of Mucosal Immunology, Graduate School of Medicine, Chiba University,

<sup>2</sup> Division of Innate Immune Regulation, International Research and Development Center for Mucosal Vaccines, Institute of Medical Science, The University of Tokyo

【P-04】

Title: Development of bivalent subunit fusion vaccine for the prevention of toxin-mediated pathogenesis of *Clostridium perfringens* and enterohemorrhagic *Escherichia coli*

(ウエルシュ菌エンテロトキシンと腸管出血性大腸菌2型ベロ毒素を標的とした2価サブユニット融合ワクチンの開発)

First author : 細見 晃司 / Koji Hosomi

Affiliation : Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN

**【P-05】**

Title:Development of Th2-Biasing CD1d Ligands Containing Modified Lipid Moieties

(脂質部位の構造展開を基盤とする Th2 サイトカイン選択的 CD1d リガンドの創製研究)

First author : 井貫 晋輔 / Shinsuke Inuki

Affiliation : <sup>1</sup> Faculty of Science and Technology, Keio University,  
<sup>2</sup>Graduate School of Pharmaceutical Sciences, Kyoto University

**【P-06】**

Title:Development of mycobacterial glycolipids-based adjuvants using nano particle technology

(ナノ粒子技術による結核菌糖脂質アジュバントの開発)

First author : 渡邊 美幸 / Miyuki Watanabe

Affiliation :Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University

**【P-07】**

Title:Roles of SOCS1 for establishment of mycobacterial infection

(マイコバクテリア感染の確立における SOCS1 の役割)

First author : 相馬 祥吾 / SOMA Shogo

Affiliation : <sup>1</sup> Tsukuba Primate Research Center, NIBIOHN, <sup>2</sup>Mie University Graduate School of Medicine

**【P-08】**

Title:Innovative nanoparticle vaccine encapsulating nucleic acids against emerging infectious diseases

First author :Nao Jonai

Affiliation :Vaccine Research Laboratories, Kitasato Daiichi Sankyo Vaccine Co., LTD.

**【P-09】**

Title:Combination of CpG ODN and STING ligand functions as Th1-inducing adjuvant

First author : Etsushi Kuroda

Affiliation : <sup>1</sup>Laboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research  
(CVAR),NIBIOHN  
<sup>2</sup>Laboratory of Vaccine Science, WPI Immunology Frontier Research Center, Osaka University

**【P-10】**

Title:A systems analysis of whole organ adjuvant transcriptomes for biomarker and target discovery

First author : Lokesh P. TRIPATHI

Affiliation :Laboratory of Bioinformatics , NIBIOHN

**【P-11】**

Title:Establishment of a novel safety profiling system for vaccines and adjuvants using the genes  
expression profile and statistical model

(マーカー遺伝子を用いた探索的な in vivo アジュバント生物活性・安全性プロファイリング法の構築)

First author : Eita Sasaki

Affiliation :Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease

**【P-12】**

Title:Construction of a Transcriptome-based Toxicity and Efficacy Prediction Model of Adjuvants

(トランスクリプトームに基づいたアジュバントの安全性および有効性の評価法の構築)

First author : Natsuko Kishishita

Affiliation : <sup>1</sup>Laboratory of Mockup Vaccine, NIBIOHN, <sup>2</sup>Laboratory of Adjuvant Innovation, NIBIOHN, <sup>3</sup> Laboratory of Vaccine Science, Immunology Frontier Research Center, World Premier International Research Center, Osaka University

**【P-13】**

Title:Assessment of K3-SPG, nano-particulate CpG DNA, as an immunotherapeutic agent in non-human primate models in vivo

(非ヒト霊長類による in vivo でのナノ微粒子化 CpG DNA である K3-SPG の免疫治療剤としての評価)

First author : 升田 雄士 / Yuji Masuta

Affiliation :<sup>1</sup>Laboratory of Adjuvant Innovation, NIBIOHN

<sup>2</sup>Laboratory of Vaccine Science, Immunology Frontier Research Center, World Premier International Research Center, Osaka University

**<Poster Layout (Science Hall) >**



**ワクチン・アジュバント研究センターキックオフミーティング プログラム・講演要旨集**

Center for Vaccine and Adjuvant Research (CVAR) Kick-Off meeting Program and Abstracts  
(October 20, 2017, Senri Life Science Center, Osaka, Japan)

Copyright © 2017 All rights reserved (不許複製・禁無断転載) 出版：2017年10月20日

発行：国立研究法人医薬基盤・健康・栄養研究所内 CVAR キックオフミーティング事務局